Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017638 (glioma)
 30,880 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 80 specimens of human glioma the production of glial fibrillary acidic protein (GFAP) by tumour cells invading meninges or connective tissue was studied immuno-cytochemically by the PAP technique. In 38 of 55 cases of astrocytoma, glioblastoma, gliosarcoma, and oligoastrocytoma, GFAP immunoreactivity was greater in the invading cells as compared with the main part of the neoplasm. Fifty-eight percent of the astroglial tumours invading the leptomeninges, all astroglial tumours invading connective tissue and all gliosarcomas showed enhanced GFAP immuno-reactivity of tumour cells getting in contact with collagenous tissue, whereas meningeal infiltrates of 25 non-astroglial tumours (oligodendroglioma, ependymoma, medulloblastoma) remained GFAP-negative like the main part of the respective tumours. In the majority of astroglial tumours an increase of GFAP immunoreactivity was found also in perivascular cells of the main part of the tumour. It is concluded that glioma cells are capable of adapting their cytoskeleton to their micro-environment. Contact with dense collagenous tissue appears as an important factor able to induce an increased production of GFAP by adjacent glial cells.
 ...
PMID:Production of glial fibrillary acidic protein (GFAP) by neoplastic cells: adaptation to the microenvironment. 639 Oct 69

In a follow up study of 38 patients with supratentrial malignant glioma verified histologically during the 3 years from 1979 to 1982, the same therapeutic method which was the postoperative synchronized radiation-immunochemotherapy was applied. And we investigated the relationships between the survival rate and the histological malignancy, the operative area, and age of admission. Total dose of 5000 to 6000 rad radiation was given after surgery. 0.02 mg/kg of VCR was administered intravenously on the first and the 29th day of radiation, and 2 mg/kg of ACNU was administered intravenously 24 hours after VCR administration. After synchronized radiotherapy, 2 mg/kg of ACNU was given every 6 weeks and 3 g of PS-K was given orally every day. Dose of PS-K was increased especially during the radiation and for 2 weeks after ACNU administration. This radioimmunochemotherapy was applied to 38 patients with malignant glioma, 25 cases of glioblastoma multiforme, 12 cases of malignant astrocytoma, one cases of malignant ependymoma, one case of malignant oligodendroglioma. A complete clinical course of all patients was observed. 18 of 38 cases are surviving. The survival rate of malignant gliomas was 71.2% for one year, 47.6% for 2 years, 34.8% for 3 years. The survival rate of glioblastoma was 56.3% for one year, 36.9% for 2 years, 12.3% for 3 years. The survival rate of the patients receiving macroscopically total removal was higher than that of the patients receiving subtotal removal. The survival rate of the younger patients (under 49 years old) was higher than that of the older patients (over 50 years old). Side effect of this therapy was myelosupression in 75.8%.
 ...
PMID:[Evaluation of radiation immunochemotherapy in the treatment of malignant glioma. Combined use of ACNU, VCR and PS-K]. 658 94

The clinical, surgical, and pathological data from 35 published cases of oligodendroglioma and of one personal case are analysed and compared with those from other tumours of the cord and from cerebral oligodendrogliomas. Oligodendroglioma of the cord has a slightly lower average age than other gliomas and is closer to that of glioblastoma. In oligodendroglioma of the cord, as of the brain, acute onset or aggravation of the symptoms and an oscillating course are frequent. Two correlated data are particularly worth noting: a) the mean CSF protein content in oligodendroglioma of the cord is higher than in any other glioma; b) intracranial hypertension, in the form of papilloedema or hydrocephalus, or both, was present in 31% of cases. This signifies cerebral oligodendrogliomatosis, which was found in 6 out of 10 necropsied cases. At operation most oligodendrogliomas of the cord appear as infiltrating "gelatinous" tumours, though a minority have a firm consistency and apparently clearcut contours, which seem to be associated with a better prognosis. Postoperative radiotherapy seems to be useful.
 ...
PMID:Oligodendrogliomas of the spinal cord. 699 45

The tumorigenicity of neonatally administered N-ethyl-N-nitrosourea (ENU) was studied in four different inbred strain rats, that is Wistar/Furth (WF), Long-Evans (LE), F1 of Wistar/Furth and Long-Evans (F1) and Fischer 344 (F344) rats. All strains developed tumors of the nervous system with high incidence (97-100%) during 6 months of observation. The incidence of tumor of the central nervous system, including the brain (82-88%) and the spinal cord (53-76%), was high in all strains, but that of the peripheral nervous system, including the cranial nerve (21-89%) and the spinal root (13-93%), differed by strain. The peripheral nervous system of WF and F344 rats had a low susceptibility to the tumorigenic effect of ENU, but that of LE rats had a high susceptibility. Many brain tumors were induced in the temporal and frontal cortex and subcortex in all strains of rats. Spinal cord tumors were observed at all levels of the white matter of the spinal cord without any predilection site. Spinal root tumors were located in lumbosacral plexuses in WF and F344 rats, but in LE and F1 rats cervical and thoracic root tumors were also observed. Histological examination revealed that most of the brain and spinal cord tumors were oligodendroglioma, but in F344 rats about half of the brain tumors were mixed glioma. Epidermoid cysts of the lumbar spinal cord were observed only in F344 rats. Tumors of the peripheral nervous system were so-called anaplastic schwannoma.
 ...
PMID:Strain differences of tumorigenic effect of neonatally administered N-ethyl-N-nitrosourea in rats. 711 58

Transplanted lines of seven F-344 (Fischer) rat malignant gliomas induced transplacentally with ethylnitrosourea (ENU) were surveyed by in vivo immunoprotection assays for the presence of tumour rejection antigens. These gliomas were representative of commonplace histological types of human primary brain tumours and were analyzed in early transplantation passages. The classical tumour ligation method of immunizing animals was attempted with five glioma lines, but was found unusable in four of these because of a high incidence of local tumour recurrences and distant metastases. In most experiments the animals were immunized by repeated inoculations of heavily-irradiated tumour cells. Two gliomas, a glioblastoma multiforms and a mixed astrocytoma-ependymoma, demonstrated weak but statistically significant tumour rejection responses. Immunization with three other tumours, a mixed oligodendroglioma-astrocytoma and two glioblastomas multiforme, led to enhanced outgrowth of the challenge cell inocula. Neither a rejection nor an enhancement response was observed in assays of the remaining two neoplasms, a glioblastoma multiforme and a mixed astrocytoma-oligodendroglioma. Immunization with a 3-methylcholanthrene-induced urinary bladder carcinoma line, used as a control in assays of six gliomas, had no effect on the outgrowth of transplanted glioma cells. These results suggest that ENU-induced malignant rat gliomas do not uniformly elicit strong tumour-rejection responses in vivo.
 ...
PMID:A survey of ethylnitrosourea-induced rat gliomas for the presence of tumour rejection antigens expressed in vivo. 723 38

To provide the significance of LDH isozymes in rat CNS tumors, the changes in lactic dehydrogenase isozyme and calculated ratios of H- to M- subunit were studied by means of polyacrylamide gel enzymoelectrophoresis in tumor extracts from CNS tumors (7 astrocytomas, 4 oligodendrogliomas, 7 mixed gliomas, 6 anaplastic gliomas, 3 glioependymomas, 1 astroblastoma, 11 neurinomas, 8 anaplastic neurinomas and 1 meningioma in Wistar rats which were induced by ethylnitrosourea). The isozyme patterns were compared to those obtained from normal rat CNS tissues. Among the glioma group, oligodendroglioma showed the highest H/M ratio followed by mixed glioma, glioependymoma, astrocytoma, astroblastoma and anaplastic glioma in order of decreasing of H/M ratios. On the other hand, the H/M ratio of neurinoma was significantly higher than that of anaplastic neurinoma. These observation suggested that determination of LDH isozyme patterns could supplement the histological evaluation of brain tumors.
 ...
PMID:LDH isozyme analyses of ethylnitrosourea-induced central nervous system tumors in rats. 739 14

This study was undertaken to evaluate the influence of hyperventilation (HV) as a test on the image contrast of brain glial tumors in enhanced magnetic resonance (MR) imaging. HV was performed for 2 min (30 breaths/min) before intravenous injection of Gd-DTPA (Magnevist), Schering AG, Germany, in a dose of 0.1 mmol/kg. A total of 19 patients with glial tumors of the brain were examined. After the functional test, the image contrast of tumor tissue was compared with tumor contrast after the standard enhanced MR imaging. Nineteen patients with brain tumors were assessed. The tumor types were histologically verified in all cases (nine malignancy degree I-II astrocytomas, six malignancy degree III astrocytomas, three ependymomas, one malignant oligodendroglioma). MRI was performed on a Magnetom 42 SP-1.0 T. There was an increase in the image contrast of degree I-II astrocytomas neither after the standard enhanced MRI nor after it in the presence of HV. On the contrary, in 2 cases there was an opposite effect--the tumor contrast decrease after the functional test. Ependymomas showed patterns of increases in contrast intensity from 10 to 13% as compared with the enhanced standard MRI in all cases. In these conditions the intrinsic structure and boundaries of tumors became more distinguished. Cases with malignant astrocytomas and oligodendroglioma had contrast enhancement increases as well. It is concluded that in cases with degree I-II astrocytomas, the use of HV does not improve the visualization of lesions. In ependymomas and anaplastic astrocytomas, HV aids in more significantly assessing the intrinsic structure and the extent of tumorigenesis and it may be useful as a functional test to assess the anaplastic extent of glial tumors of the brain and as a procedure enabling the contrast agent to be used in smaller dosages.
 ...
PMID:[The use of hyperventilation for improving the visualization of glial tumors of the brain in magnetic resonance tomography using the contrast substance Gd-DTPA]. 748 47

Allelic mutation on chromosome 19 has previously been reported as a frequent genetic event in human glial tumors. In an effort to localize specific regions of importance on this chromosome better, 13 highly polymorphic genetic markers distributed along the length of chromosome 19 were used for evaluation of loss of heterozygosity (LOH) and microsatellite instability in a total of 100 brain tumors, including 75 astrocytomas (55 grade 4; 7 grade 3; 5 grade 2; 6 grade 1; and 2 other), 17 oligodendrogliomas (1 grade 4; 5 grade 3; 10 grade 2; and 1 grade 1), and 8 mixed oligoastrocytomas (MOA) (3 grade 4; 2 grade 3; and 3 grade 2). No microsatellite expansion was observed in these glial tumors for any of the chromosome 19 loci examined. LOH for loci on chromosome 19 was detected in 23/74 informative astrocytomas (31%), 11/17 oligodendrogliomas (65%), and 3/8 MOA (38%). Partial deletion of chromosome 19 occurred more frequently (31/37 cases) than did loss of one whole copy of the chromosome, and a morphology-specific pattern of LOH was observed. In 12/14 (86%) instances of chromosome 19 deletion in oligodendrogliomas and MOA, the 19q arm showed LOH, whereas the 19p arm showed no loss for all informative loci. Conversely, in 17/23 (74%) instances of chromosome 19 deletion in astrocytomas, the 19p arm showed LOH, whereas the 19q arm showed no loss for one or more loci. Thus, loss of 19q and retention of 19p are strongly associated with oligodendroglioma and MOA, whereas loss of 19p and retention of distal 19q is associated with astrocytoma.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. 753 82

Recent studies have suggested that the triphenylethylene antiestrogen tamoxifen inhibits the proliferation in vitro of a substantial percentage of cell lines derived from adult high-grade gliomas, potentially acting through inhibition of the second messenger protein kinase C. These findings have formed the impetus for clinical trials of this agent in adults with malignant gliomas. However, it has previously remained uncertain whether tamoxifen has a similar inhibitory effect on the proliferation of pediatric high-grade gliomas, and whether low-grade gliomas, which constitute the majority of glial neoplasms in children, are also inhibited by this agent. To address these issues, the present study examined the effect of tamoxifen on proliferation and viability in a series of low-passage cell lines derived both from low-grade and high-grade pediatric gliomas. This agent was tested in three malignant gliomas, two pilocytic astrocytomas, two non-pilocytic low-grade astrocytomas, 1 mixed glioma, and 1 oligodendroglioma. Tamoxifen produced a dose-dependent inhibition of proliferation in two of the three malignant glioma cell lines and in each of the low-grade glioma cell lines with a 50% effective dose of approximately 3 micrograms/ml (5.4 microM), which is comparable to the IC50 for inhibition of PKC activity by this agent. No significant cytotoxicity was encountered at this concentration. However, complete elimination of proliferation was achieved with a dose of 10 micrograms/ml (17.8 microM), which produced a direct cytotoxic effect. We conclude that tamoxifen inhibits proliferation of cell lines derived from both low-grade and high-grade pediatric glial tumors in vitro at concentrations that may be achievable clinically with high-dose oral therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. 757 61

Chromosome 19q harbors a tumor suppressor gene that is involved in astrocytoma, oligodendroglioma and mixed glioma tumorigenesis. We had previously mapped this gene to an approximately 5 megabase region of chromosome 19q13.2-13.3 between APOC2 and HRC. To narrow the location of this tumor suppressor further, we studied 138 gliomas for loss of allelic heterozygosity at six microsatellite polymorphisms between APOC2 and HRC, including a newly described polymorphism in the ERCC2 gene. Allelic loss occurred in 48 gliomas (35%), including 25 of 41 oligodendroglial tumors (61%). Four cases had proximal breakpoints within the APOC2-HRC region, two telomeric to ERCC2 and two telomeric to D19S219. In addition, one of the latter tumors had an interstitial deletion between D19S219 and D19S112, a distance of only 425 kilobases surrounding the DM (myotonic dystrophy) gene. These findings suggest that the glioma tumor suppressor on chromosome 19q maps to 19q13.3, telomeric to D19S219 and perhaps centromeric to D19S112. The data exclude a number of candidate genes from 19q13.2-13.3, including a putative phosphatase gene and the DNA repair/metabolism genes ERCC1, ERCC2 and probably LIG1.
 ...
PMID:Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. 766 49


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>